AUA 2019: Intralesional Injection of Collagenase Clostridium histolyticum for Management of Peyronie’s Disease with Indentation or Hourglass Deformity

Chicago, IL ( The only FDA approved treatment of stable phase Peyronie’s Disease (PD) is an intralesional injection (ILI) of collagenase clostridium histolyticum (CCH). To this end, Mahdi Osman, the clinical research coordinator for Dr. Faysal Yafi, sought to outline the outcomes of treatment with ILI CCH for patients with PD and extensive indentation or hourglass deformity.

Their retrospective study reviewed 13 patients that were treated with ILI CCH and fit the criteria of having either significant indentation or hourglass deformity: 8 and 5 respectively. Osman clarifies that patients with an indentation had treatment only if they had palpable plaque, otherwise this treatment was not offered. Patients who chose this treatment were given an average of 8.3 injections, with a standard deviation of 3.1 injections. There was a significant improvement in curvature (77.8%) when patients had 8 or more injections. There was also a 65.3% subjective, reported resolution and an average of 6.8 with a standard deviation of 2.9 bother score in patients after surgery.

Osman concludes that the study demonstrates favorable outcomes in patients, both subjectively and objectively, through bother scores and penile curvature respectively. He suggests that the ILI CCH treatment should include patients with significant indentation and hourglass deformities.

Presented by: Mahdi Osman, University of California, Irvine, Dept. of Urology, Orange, California

Written by: Joshua Tran, Department of Urology, University of California-Irvine at American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois 
email news signup